ChemoCentryx (CCXI) Phase 2 Trial of CCX140 Met Primary Endpoint
Tweet Send to a Friend
ChemoCentryx, Inc., (Nasdaq: CCXI) today announced positive top-line 52-week data from its Phase II clinical trial in diabetic nephropathy with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE